Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRISTAR: High-frequency Aflibercept in Refractory nAMD
NCT03468296Phase 4Unknown
- Sponsor
- Tennessee Retina
- Start
- Apr 2018
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Tennessee Retina. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03468296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468296.